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MAGNETICALLY TRIGGERABLE ELECTROACTIVE COMPOSITES,
METHOD OF MAKING THE MAGNETICALLY TRIGGERABLE
ELECTROACTIVE COMPOSITES, AND METHOD OF USING THE
MAGNETICALLY TRIGGERABLE ELECTROACTIVE COMPOSITES
CLAIM OF PRIORITY TO RELATED APPLICATION
This application claims priority to co-pending U.S. application entitled
"Magnetically Triggerable Electroactive Biomaterials" having Serial No. 62/100,284,
filed on January 6, 2015, which is entirely incorporated herein by reference.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
This invention was made with government support under grant numbers
DMR-1 150665 and DMR-1410564, awarded by the National Science Foundation.
The government has certain rights in the invention.
BACKGROUND
It has been suggested to deliver drugs in vivo by encapsulating them in an
electroactive biomaterial and then applying an electrical potential to the biomaterial.
This would require an electrical connection (usually a wire) between an electrical
power source and the electroactive material implanted in the patient. It would be
advantageous to be able to deliver drugs in vivo without the need to make an
electrical connection with the patient.
SUMMARY
Embodiments of the present disclosure provide for magnetically triggered
electroactive composites, methods of making the magnetically triggered electroactive
composites, methods of using the magnetically triggered electroactive composites,
and the like.
An embodiment of the present disclosure provides for a composite, among
others, that includes: a matrix of an electroactive polymer and a magnetoelectric
material. In an embodiment, the electroactive polymer includes an aromatic
functional group. In a particular embodiment, the electroactive polymer is selected
from the group consisting of: polypyrrole, polyaniline, polythiophene, poly(3,4-
ethylenedioxythiophene), poly fluorenes, polyphenylenes, polypyrenes, polyazulenes,
polynapthalenes, polyindoles, polyazepines, poly(p-phenylene sulfide)s, poly(p-
phenylene vinylene)s, and polyfurans. In an embodiment, the electroactive polymer
can be biodegradable and can contain electroactive oligomeric components. In an
embodiment, the oligomeric component can be water-soluble and can have a
molecular weight of about 1,000 to 70,000 Daltons. In an embodiment, the
magnetoelectric material comprises a piezoelectric material and a magnetostrictive
material.
In an embodiment, the present disclosure includes a method of delivering an
agent, among others, that includes: introducing a composite to a subject, wherein the
composite includes a matrix of an electroactive polymer and a magnetoelectric
material, wherein the composite includes the agent; subjecting the composite to an
external magnetic field, wherein the magnetoelectric material produces an electrical
field in response to the magnetic field; and releasing the agent from the composite so
the agent interacts with the subject.
BRIEF DESCRIPTION OF THE DRAWINGS
Many aspects of the present disclosure can be better understood with reference
to the following drawing.
Fig. 1 is a schematic diagram of an electroactive composite material in
accordance with a preferred embodiment, in which the magnetoelectric
particles/fibers are incorporated within the electroactive polymer (e.g. a biodegradable
electroactive polymer), and the particles and electroactive polymer interact though
non-covalent/physical interactions.
Fig. 2 is a schematic of electroactive polymers in accordance with a preferred
embodiment, in which the magnetoelectric nanoparticles or nanofibers are
incorporated within the electroactive polymer, and the electroactive polymer is
covalently attached to the magnetoelectric nanoparticles/nanofibers (in this example,
the electroactive polymer is polypyrrole, PPy) and dexamethasone phosphate (DMP)
is an example of a therapeutic drug encapsulated in the matrix.
Fig. 3 shows the release of DMP from the composite of the present disclosure,
such as the composite in Figure 1.
Fig. 4 schematically illustrates the electrospinning set-up for bi- and tri-layer
fibers, and the resultant morphologies, including bi-layer c) particles and d) fibers and
e) tri- and f) six layered fibers.
Fig. 5 shows Fourier Transform Infrared (FTIR) spectra confirming successful
surface modification of the as-synthesized Janus-type magnetoelectric fibers and
fibers surface modified with -thiol, poly(ethylene glycol) (PEG), and
aminopropyltriethoxysilane (APTMS) groups.
Fig. 6 a) is a graph that shows the results of a lactase dehydrogenase (LDH)
assay, which measures LDH that is released by dead, dying, or damaged cells,
revealing that bare, polyethylene glycol-, and thiol-functionalized Janus fibers are not
cytotoxic.
Fig. 6 b) is a bright field image of the fibers.
Fig. 6 c) is a Live/Dead assay showing that the cells preferentially grow on the
functionalized magnetoelectric fibers.
DISCUSSION
This disclosure is not limited to particular embodiments described, and as such
may, of course, vary. The terminology used herein serves the purpose of describing
particular embodiments only, and is not intended to be limiting, since the scope of the
present disclosure will be limited only by the appended claims.
Where a range of values is provided, each intervening value, to the tenth of the
unit of the lower limit unless the context clearly dictates otherwise, between the upper
and lower limit of that range and any other stated or intervening value in that stated
range, is encompassed within the disclosure. The upper and lower limits of these
smaller ranges may independently be included in the smaller ranges and are also
encompassed within the disclosure, subject to any specifically excluded limit in the
stated range. Where the stated range includes one or both of the limits, ranges
excluding either or both of those included limits are also included in the disclosure.
As will be apparent to those of skill in the art upon reading this disclosure,
each of the individual embodiments described and illustrated herein has discrete
components and features which may be readily separated from or combined with the
features of any of the other several embodiments without departing from the scope or
spirit of the present disclosure. Any recited method may be carried out in the order of
events recited or in any other order that is logically possible.
Embodiments of the present disclosure will employ, unless otherwise
indicated, techniques of organic chemistry, biochemistry, microbiology, molecular
biology, pharmacology, medicine, and the like, which are within the skill of the art.
Such techniques are explained fully in the literature.
Prior to describing the various embodiments, the following definitions are
provided and should be used unless otherwise indicated.
Unless otherwise defined, all technical and scientific terms used herein have
the same meaning as commonly understood by one of ordinary skill in the art of
microbiology, molecular biology, medicinal chemistry, and/or organic chemistry.
Although methods and materials similar or equivalent to those described herein can be
used in the practice or testing of the present disclosure, suitable methods and materials
are described herein.
As used in the specification and the appended claims, the singular forms "a,"
"an," and "the" may include plural referents unless the context clearly dictates
otherwise. Thus, for example, reference to "a support" includes a plurality of
supports. In this specification and in the claims that follow, reference will be made to
a number of terms that shall be defined to have the following meanings unless a
contrary intention is apparent.
Definitions:
By "administration" is meant introducing a magnetically triggered
electroactive composite of the present disclosure into a subject. The route of
administration can include any route of administration, such as intravenous oral,
topical, subcutaneous, peritoneal, intraarterial, inhalation, vaginal, rectal, nasal,
introduction into the cerebrospinal fluid, or instillation into body compartments can be
used. In regard to the agent, the agent can be administered to the subject via the
magnetically triggered electroactive composite, where the agent can be subsequently
released upon application of a magnetic field to the magnetically triggered
electroactive composite.
The terms "therapeutically effective amount" and "an effective amount" are
used interchangeably herein and refer to that amount of the magnetically triggered
electroactive composite or an agent being administered that is sufficient to effect the
intended application including, but not limited to, condition treatment. For example,
an effective amount of the agent will relieve to some extent one or more of the
symptoms of the condition, i.e., infection, being treated, and/or that amount that will
prevent, to some extent, one or more of the symptoms of the disease, i.e., infection,
that the host being treated has or is at risk of developing. The therapeutically
effective amount may vary depending upon the intended application (in vitro or in
vivo), or the subject and disease condition being treated, e.g., the weight and age of
the subject, the severity of the disease condition, the manner of administration and the
like, which can readily be determined by one of ordinary skill in the art. The specific
dose will vary depending on the particular agent chosen, the dosing regimen to be
followed, whether it is administered in combination with other agents, timing of
administration, the tissue to which it is administered, and the physical delivery system
in which it is carried.
The term "unit dosage form," as used herein, refers to physically discrete units
suitable as unitary dosages for human and/or animal subjects, each unit containing a
predetermined quantity of the agent calculated in an amount sufficient to produce the
desired effect in association with a pharmaceutically acceptable diluent, carrier or
vehicle. The specifications for unit dosage forms depend on the particular agent
employed, the route and frequency of administration, and the effect to be achieved,
and the pharmacodynamics associated with each agent in the subject.
As used herein, a "pharmaceutical composition" and a "pharmaceutical
formulation" are meant to encompass embodiments of the present disclosure or agent
suitable for administration to a subject, such as a mammal, especially a human. In
general, a "pharmaceutical composition" or "pharmaceutical formulation" is sterile,
and preferably free of contaminants that are capable of eliciting an undesirable
response within the subject (e.g., the agent or the polymer assembly in the
pharmaceutical composition is pharmaceutical grade). Pharmaceutical compositions
can be designed for administration to subjects or patients in need thereof via a number
of different routes of administration including oral, intravenous, buccal, rectal,
parenteral, intraperitoneal, intradermal, intracheal, intramuscular, subcutaneous,
inhalational and the like.
As used herein, the terms "treatment", "treating", and "treat" are defined as
acting upon a condition with an agent to reduce or ameliorate the pharmacologic
and/or physiologic effects of the condition and/or its symptoms. "Treatment", as used
herein, covers any treatment of a condition in a subject (e.g., a mammal, typically a
human or non-human animal of veterinary interest), and includes: (a) reducing the
risk of occurrence of the condition in a subject determined to be predisposed to the
condition but not yet diagnosed with the condition (b) impeding the development of
the condition, and (c) relieving the condition, i.e., causing regression of the condition
and/or relieving one or more condition symptoms. "Treatment" is also meant to
encompass delivery of agent or polymer assembly to provide a pharmacologic effect,
even in the absence of a condition. For example, "treatment" encompasses delivery of
an agent or polymer assembly that provides for enhanced or desirable effects in the
subject.
As used herein, the terms "prophylactically treat" and "prophylactically
treating" refer completely or partially preventing a condition or symptom thereof
and/or may be therapeutic in terms of a partial or complete cure for a condition and/or
adverse effect attributable to the condition.
As used herein, the term "subject" includes humans, mammals (e.g., cats,
dogs, horses, etc.), birds, and the like. Typical subjects to which embodiments of the
present disclosure may be administered will be mammals, particularly primates,
especially humans. For veterinary applications, a wide variety of subjects will be
suitable, e.g., livestock such as cattle, sheep, goats, cows, swine, and the like; poultry
such as chickens, ducks, geese, turkeys, and the like; and domesticated animals
particularly pets such as dogs and cats. For diagnostic or research applications, a
wide variety of mammals will be suitable subjects, including rodents (e.g., mice, rats,
hamsters), rabbits, primates, and swine such as inbred pigs and the like. Additionally,
for in vitro applications, such as in vitro diagnostic and research applications, body
fluids and cell samples of the above subjects will be suitable for use, such as
mammalian (particularly primate such as human) blood, urine, or tissue samples, or
blood, urine, or tissue samples of the animals mentioned for veterinary applications.
In some embodiments, a system includes a sample and a host. The term "living host"
refers to the entire host or organism and not just a part excised (e.g., a liver or other
organ) from the living host.
Discussion :
Embodiments of the present disclosure provide for magnetically triggered
electroactive composites, methods of making the magnetically triggered electroactive
composites, methods of using the magnetically triggered electroactive composites,
and the like. In an embodiment, the magnetically triggered electroactive composite
has electroactive characteristics so that an electrical stimulation can be periodically
applied to the magnetically triggered electroactive composite, where an electric field
(e.g., electrical stimulation) can be produced as a result of applying a magnetic field
onto the magnetoelectric material which causes current flow in the electroactive
polymer. In this regard, the magnetically-triggerable electroactive composite can be
used to deliver drugs or to stimulate cells or tissue.
In an embodiment, the magnetically triggered electroactive composite includes
a matrix of an electroactive polymer and a magnetoelectric material. The
magnetoelectric material can be dispersed throughout the electroactive polymer. In an
embodiment, the magnetoelectric material can be in the form of a scaffold that
supports the electroactive polymer or the electroactive polymer can be in the form of a
scaffold that supports the magnetoelectric material. Subjecting the matrix to a
magnetic field (e.g., externally applied) causes the matrix to become electrically
active. In addition, one or more agents can be disposed in the matrix and released
from the matrix when the matrix is exposed to an appropriate magnetic field. In this
regard, the magnetically triggered electroactive composite of the present disclosure
can be used to deliver agents such as drugs, antibacterial agents, and antifungal
agents. In addition, the magnetically triggered electroactive composite can also be
used as electroactive actuators capable of mechanotransduction of cells, such as stem
cells, or tissue.
In an embodiment the electroactive polymer and the magnetoelectric material
can interact with one another covalently and/or non-covalently. In an embodiment,
the electroactive polymer and the magnetoelectric material can interact with one
another through covalent bonds or non-covalent physical interactions (e.g., chain
entanglement), which can yield an interpenetrating network.
In an embodiment the matrix can be embodied in any of a variety of material
morphologies or combination of morphologies (e.g., scaffolds, fibers, films, foams,
gels, particulates, and combinations thereof), optionally with micrometer or
nanometer-scale features (e.g., grooves, bumps, pores, where the grooves and pores
can be an indention into the surface and/or extend through the matrix). In an
embodiment, the magnetoelectric material can be a fiber(s) (e.g., nanofibers) or a
particulate(s) (e.g., nanoparticles) that can be part of and/or form a scaffold that can
interact with the electroactive polymer.
In an embodiment the matrix can be biodegradable. In an embodiment, the
electroactive polymer is water soluble, which facilitates degradation of the entirety of
the material. The term "biodegradable" refers to polymers that degrade through the
action of a physicochemical (e.g., hydrolysis, pH) or biological (e.g., enzyme) trigger
that the polymer is exposed to in use.
In an embodiment, the electroactive polymer can include an aromatic
functional group. The aromatic functional group can be non-heterocyclic or
heterocyclic group. In an embodiment, the electroactive polymer can include a
pyrrole, an aniline, an aniline derivative, a furan, a furan derivative, a thiophene, a
thiophene derivative (e.g., poly(3,4-ethylenedioxythiophene)), ferrocene, a ferrocene
derivative, a porphyrin, a porphyrin derivative, a fluorine, a fluorene derivative, the
polymerizable unit include a phenylene, a phenylene derivative, a pyrene, a pyrene
derivative, an azulene, an azulene derivative, a naphthalene, a napthalene derivative,
an indole, an indole derivative, an azepinesp-phenylene, an azepinesp-phenylene
derivative, a sulfide p-phenylene vinylene, a sulfide p-phenylene vinylene derivative,
or a combination thereof, each of which can be a polymer, co-polymer of two or more
monomers, and the like. In an embodiment, the electroactive polymer (conducting
polymer) can include polymers such as polypyrrole, polyaniline, polythiophene,
poly(3,4-ethylenedioxythiophene), polyfluorenes, polyphenylenes, polypyrenes,
polyazulenes, polynapthalenes, polyindoles, polyazepines, poly(p-phenylene sulfide)s,
poly(p-phenylene vinylene)s, and polyfurans. In an embodiment, there are
biodegradable versions, in which there are block of conducting units within a polymer
chain containing biodegradable bonds (e.g. esters and amides), that can also be used
as the conducting polymer. In an embodiment, the electroactive polymer can be used
in conjunction with a dopant. The dopant can be a species that has the opposite
charge to the conducting polymer, and can be low molecular weight (e.g., chlorine
ions, tosylate ions, and the like) or high molecular weight (e.g., collagen, hyaluronic
acid, and the like). In a particular embodiment, the polymerizable unit can be
polypyrrole, or more particularly, the polymerizable unit can be 3,4-
ethylenedioxythiophene; and a derivative of 3,4-ethylenedioxythiophene. The amount
of the electroactive polymer in the matrix can be about 1 to 90 wt % of the composite.
In an embodiment, the electroactive polymer is a block polymer comprising
electroactive blocks (e.g., oligoaniline blocks) linked together by biodegradable ester
bonds; and one or more other polymers (e.g., polycaprolactone or polyethylene
glycol). In an embodiment, the other polymer can include synthetic polymers (e.g.,
polycaprolactone, polyesters, polyamides, PCL, PLLA, PLGA, etc.), natural polymers
(e.g. proteins, polysaccharides, lignins, polyalanine, oligoalanine, collagen, silk,
cellulose, chitin, chitosan, and the like), or a combination thereof. In a particular
embodiment, the other polymer can include a polycaprolactone polymer. In an
embodiment, the other polymer can include a mixture of different types of polymer
(e.g., a portion of polycaprolactone and polyester). In an embodiment, the
electroactive polymer is a block polymer comprising electroactive oligoaniline blocks
linked together by biodegradable ester bonds; and polycaprolactone or polyethylene
glycol (or derivatives thereof). In an embodiment, the other polymer can have a
molecular weight of about 400 to 100,000 Daltons, about 400 to 10,000 Daltons, or
about 400 to 2,000 Daltons. The amount of the other polymer in the matrix can be
about 1 to 80 wt % of the composite.
In an embodiment, the magnetoelectric material can include one or more
components. In an embodiment, the magnetoelectric material can be an organic
material (e.g., oligomer, polymer) or an inorganic material (e.g., metal or metal based
compound). In an embodiment, the magnetoelectric material can be about 1 to 80 %
wt. of the composite.
In an embodiment, the magnetoelectric material can be an oligomer or
polymer. In an embodiment, the magnetoelectric material can be an oligomer that is
water-soluble and has a molecular weight of about 1000 to 70,000 Daltons. In an
embodiment, the oligomer can be in the form of a particle (e.g., nanoparticle having a
largest dimension of about 5 to 500 nm or about 5 to 50 nm) or fiber (e.g., a nanofiber
having a diameter of about 5 to 500 nm or about 5 to 50 nm and an aspect ratio of 10
to 100,000).
In an embodiment, the oligomer can be oligomers of: pyrrole, an aniline, an
aniline derivative, a furan, a furan derivative, a thiophene, a thiophene derivative
(e.g., 3,4-ethylenedioxythiophene), ferrocene, a ferrocene derivative, a porphyrin, a
porphyrin derivative, a fluorine, a fluorene derivative, the polymerizable units include
a phenylene, a phenylene derivative, a pyrene, a pyrene derivative, an azulene, an
azulene derivative, a naphthalene, a napthalene derivative, an indole, an indole
derivative, an azepinesp-phenylene, an azepinesp-phenylene derivative, a sulfide p-
phenylene vinylene, a sulfide p-phenylene vinylene derivative, or a combination
thereof . In an embodiment, the oligomer can have a molecular weight of about 500
to 5,000 Da.
In an embodiment, the magnetoelectric material can include a piezoelectric
material and/or a magnetostrictive material. In an embodiment, the piezoelectric
material can be: barium titanate, bismuth ferrite, polyvinylidene difluoride, lead
zirconate titanate, polyvinylidene difluoride- trifluoroethylene, or a combination
thereof. In an embodiment, the magnetostrictive material can be: cobalt ferrite, iron
oxide, terfenol-d, or a combination thereof. In an embodiment, the ratio of the
piezoelectric material to the magnetostrictive material can be about 1:99 to 99 :1. In an
embodiment, the magnetoelectric material can be piezoelectric barium titanate and
magnetostrictive cobalt ferrite.
In an embodiment, the composite can include one or more agents (e.g., a
chemical or biological agent), where the agent can be disposed indirectly or directly
on/in the composite. The composite can be made by a variety of different techniques,
but simple examples include films dried from suspensions of the agent, electroactive
polymer and magnetoelectric material, and optionally other components (e.g.
polymers) in solution in a suitable solvent (aqueous or non-aqueous); or melting of
one or more of the polymeric components with the agent, electroactive polymer and
magnetoelectric material; or growth of electroactive polymers from the surface of
magnetoelectric materials and their loading with an agent.
In this regard the agent can be administered to the subject to treat, image,
detect, study, monitor, and/or evaluate a condition, or the like in the subject. In an
embodiment, the agent can include, but is not limited to, a drug, a therapeutic agent, a
radiological agent, a small molecule drug, a biological agent (e.g., polypeptides (e.g.,
proteins such as, but not limited to, antibodies (monoclonal or polyclonal)), antigens,
nucleic acids (both monomeric and oligomeric), polysaccharides, haptens, sugars,
fatty acids, steroids, purines, pyrimidines, ligands, and aptamers) and combinations
thereof, that can be used to image, detect, study, monitor, evaluate, and the like, the
differentiation of the stem cells. In an embodiment, the agent is included in an
effective amount to accomplish its purpose, where such factors to accomplish the
purpose are well known in the medical arts.
In general, the agent can be bound to the composite (e.g., scaffold, particles,
fibers, polymers, and the like) by a physical, biological, biochemical, and/or chemical
association directly or indirectly by a suitable means. The term "bound" can include,
but is not limited to, chemically bonded (e.g., covalently or ionically), biologically
bonded, biochemically bonded, and/or otherwise associated with the material. In an
embodiment, being bound can include, but is not limited to, a covalent bond, a non-
covalent bond, an ionic bond, a chelated bond, as well as being bound through
interactions such as, but not limited to, hydrophobic interactions, hydrophilic
interactions, charge-charge interactions, pi-pi stacking interactions, combinations
thereof, and like interactions.
As described herein, embodiments of the present disclosure provide for a
method of delivering one or more agents. An embodiment of the method includes
providing (e.g., administering) the composite including the agent to a subject having a
condition (e.g., a disease, an infection, an injury, a syndrome, a disability, a disorder,
and a combination thereof). The composite can be administered in one or more ways
as is best suited for the particular situation. Subsequently, a magnetic field can be
applied to generate an electrical stimulus that can be used to activate composite. In
particular, the magnetic filed can be directed to an area where the agent is needed.
For example, if the condition is pain or an infection at a particular location, the
magnetic field can be directed to that area. In this way, the magnetic field causes the
agent to be released from the composite at or near the location (e.g., specific area of
the patient) of the condition. In an embodiment, the magnetic field causes the
magnetostrictive component to change shape, which imposes a strain on the
piezoelectric component - thereby generating an electric field, and this electric field
causes the release of the agent from the surrounding matrix of agent-loaded
electroactive polymer. In an embodiment, the magnetic field can be periodically
applied or pulsed. In an embodiment, the magnetic field can be applied at certain
times of the day.
In regard to electrical stimulation of cells or tissue, embodiments of the
disclosure provide for methods of stimulating cells or tissue. An embodiment of the
present disclosure includes introducing cells to the composite, where the composite
(and optionally a tissue or other cells) and the cells are cultured in an appropriate
medium. Subsequently, the composite can be exposed to a magnetic field to generate
electrical stimulation that can be periodically applied (e.g., via the magnetic field) to
the cells to cause a desired outcome.
The term "periodically" refers to applying the electrical stimulation (e.g., via
the magnetic field) at established time frames that may be at regular or irregular time
intervals on the time frames of seconds, hours, days, weeks, or months (e.g., about 1 s
to 2 months, about 1 hour to 1 day, about 1 day to 1 month, or other the like)
depending upon the specific circumstances. In an embodiment, the impulses of the
electrical stimulation can last on the time frame of seconds, hours, or days (e.g.,
about 1 second to 1 day, about 10 seconds to 1 hour, about 1 minute to 12 hours,
about 1 hour to 1 day, or the like) depending upon the specific circumstances. The
time frame and duration of electrical stimulation can be designed based on particular
circumstances and requirements of a specific situation.
While embodiments of the present disclosure are described in connection
with the Examples and the corresponding text and figures, there is no intent to limit
the disclosure to the embodiments in these descriptions. On the contrary, the intent is
to cover all alternatives, modifications, and equivalents included within the spirit and
scope of embodiments of the present disclosure.
EXAMPLE:
The release of a bioactive molecule (e.g., dexamethasone phosphate, DMP, an
anti-inflammatory) is controlled from a matrix of a biodegradable electroactive
polymer (as depicted in Figure 1). An example of such polymers are block
copolymers composed of electroactive oligoaniline blocks and non-electroactive
biodegradable polycaprolactone or polyethylene glycol, and the blocks are linked
together via biodegradable ester bonds. In a preferred embodiment, the electroactive
oligomer has a molecular weight below the renal filtration limit of 70,000 Da, and is
sufficiently water soluble to allow its clearance via the renal system upon degradation
of the polycaprolactone blocks or ester bonds. Exposure of the composite materials
(as depicted in Figure 1) composed of the magnetoelectric particles/fibers, an
electroactive polymer and a drug (DMP) to magnetic fields for specified times results
in the release of the drug (see Figure 3). The release rate can be varied by applying
and removing the field. This allows the electroactive polymer to serve as a drug
storage reservoir, which can be tapped as needed by application and removal of the
magnetic field.
Fabrication of the Electroactive Composite Materials
The electroactive composite materials in accordance with a preferred
embodiment are composed of a conducting polymer and a Janus-type magnetoelectric
nanoparticle or nanofiber (so called because the particle or fiber is made up of a
piezoelectric phase and a magnetostrictive phase that are distributed semi-
cylindrically). In a preferred embodiment, these magnetoelectric nanoparticles or
nanofibers are composed of piezoelectric barium titanate and magnetostrictive cobalt
ferrite. These magnetoelectric nanoparticles or nanofibers are synthesized via co-
electrospinning. By varying the processing conditions, fibers or particles can be
produced (Fig. 4). The as-synthesized particles are surface modified for further
functionalization for biological applications. Fig. 5 shows Fourier Transform Infrared
Spectroscopy (FTIR) results, which confirm the modification of the surface of the
fibers with thiols, amines, and polyethylene glycol. The biocompatibility of these
fibers are further confirmed in Fig. 6 . Fig. 3 reveals that these multiferroic
composites do not exhibit cytotoxicity. These results compare the biocompatibility of
as-synthesized bare fibers and fibers functionalized with polyethylene glycol and a
thiol functionality using a lactase dehydrogenase assay (LDH) which measures LDH
that is released by dead, dying or damaged cells (Fig. 6 a). Figs. 6 b) and 6 c) show
bright-field and fluorescent microscope images, respectively, of osteosarcoma cells
(MG63) on functionalized fibers, indicating that the cells preferentially adhere to the
magnetoelectric fibers.
It should be noted that ratios, concentrations, amounts, and other numerical
data may be expressed herein in a range format. It is to be understood that such a
range format is used for convenience and brevity, and thus, should be interpreted in a
flexible manner to include not only the numerical values explicitly recited as the limits
of the range, but also to include all the individual numerical values or sub-ranges
encompassed within that range as if each numerical value and sub-range is explicitly
recited. To illustrate, a concentration range of "about 0.1% to about 5%" should be
interpreted to include not only the explicitly recited concentration of about 0 .1 wt% to
about 5 wt%, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%)
and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated
range. In an embodiment, the term "about" can include traditional rounding according
to significant figures of the numerical value. In addition, the phrase "about 'x' to 'y'"
includes "about 'x' to about 'y'".
Many variations and modifications may be made to the above-described
embodiments. All such modifications and variations are intended to be included herein
within the scope of this disclosure and protected by the following claims.
CLAIMS
We claim:
1. A composite, comprising:
a matrix of an electroactive polymer and a magnetoelectric material.
2 . The composite of claim 1, wherein the electroactive polymer includes an
aromatic functional group.
3 . The composite of claim 2, wherein the electroactive polymer is selected from
the group consisting of: polypyrrole, polyaniline, polythiophene, poly(3,4-
ethylenedioxythiophene), poly fluorenes, polyphenylenes, polypyrenes, polyazulenes,
polynapthalenes, polyindoles, polyazepines, poly(p-phenylene sulfide)s, poly(p-
phenylene vinylene)s, and polyfurans.
4 . The composite of claim 1, wherein the electroactive polymer includes an
oligomer component, wherein the oligomer component is water-soluble and has a
molecular weight of about 1000 to 70,000 Daltons.
5 . The composite of claim 4, wherein the oligomer component is selected from
the group consisting of: pyrrole, an aniline, an aniline derivative, a furan, a furan
derivative, a thiophene, a thiophene derivative, ferrocene, a ferrocene derivative, a
porphyrin, a porphyrin derivative, a fluorine, a fluorene derivative, the polymerizable
units include a phenylene, a phenylene derivative, a pyrene, a pyrene derivative, an
azulene, an azulene derivative, a naphthalene, a napthalene derivative, an indole, an
indole derivative, an azepinesp-phenylene, an azepinesp-phenylene derivative, a
sulfide p-phenylene vinylene, a sulfide p-phenylene vinylene derivative,and a
combination thereof .
6 . The composite of claim 1, wherein the magnetoelectric material comprises a
piezoelectric material, a magnetostrictive material, or a combination thereof.
7 . The composite of claim 6, wherein the piezoelectric material is selected from
the group consisting of: barium titanate, bismuth ferrite, polyvinylidene difluoride,
lead zirconate titanate, polyvinylidene difluoride-trifluoroethylene, and a combination
thereof.
8 . The composite of claim 6, wherein the magnetostrictive material is selected
from the group consisting of: cobalt ferrite, iron oxide, terfenol-d, and a combination
thereof.
9 . The composite of claim 10, wherein the magnetoelectric material comprises
piezoelectric barium titanate, magnetostrictive cobalt ferrite, or a combination thereof.
10 . A method of delivering an agent, comprising:
introducing a composite to a subject, wherein the composite includes a matrix
of an electroactive polymer and a magnetoelectric material, wherein the composite
includes the agent;
subjecting the composite to a magnetic field, wherein the magnetoelectric
material produces an electrical field in response to the magnetic field; and
releasing the agent from the composite so the agent interacts with the subject.
11. The method of claim 10, wherein the electroactive polymer is selected from
the group consisting of: polypyrrole, polyaniline, polythiophene, poly(3,4-
ethylenedioxythiophene), poly fluorenes, polyphenylenes, polypyrenes, polyazulenes,
polynapthalenes, polyindoles, polyazepines, poly(p-phenylene sulfide)s, poly(p-
phenylene vinylene)s, and polyfurans.
12. The method of claim 10, wherein the electroactive polymer includes an
oligomer component, wherein the oligomer component is water-soluble and has a
molecular weight of about 1000 to 70,000 Daltons.
13 . The method of claim 10, wherein the oligomer component is selected from the
group consisting of: pyrrole, an aniline, an aniline derivative, a furan, a furan
derivative, a thiophene, a thiophene derivative, ferrocene, a ferrocene derivative, a
porphyrin, a porphyrin derivative, a fluorine, a fluorene derivative, the polymerizable
units include a phenylene, a phenylene derivative, a pyrene, a pyrene derivative, an
azulene, an azulene derivative, a naphthalene, a napthalene derivative, an indole, an
indole derivative, an azepinesp-phenylene, an azepinesp-phenylene derivative, a
sulfide p-phenylene vinylene, a sulfide p-phenylene vinylene derivative, and a
combination thereof .
14. The method of claim 10, wherein the magnetoelectric material comprises a
piezoelectric material, a magnetostrictive material, or a combination thereof.
15 . The method of claim 14, wherein the piezoelectric material is selected from
the group consisting of: barium titanate, bismuth ferrite, polyvinylidene difluoride,
lead zirconate titanate, polyvinylidene difluoride-trifluoroethylene, and a combination
thereof.
16 . The method of claim 10, wherein the magnetostrictive material is selected
from the group consisting of: cobalt ferrite, iron oxide, terfenol-d, and a combination
thereof.
17 . The method of claim 10, wherein the magnetoelectric material comprises
piezoelectric barium titanate, magnetostrictive cobalt ferrite, or a combination thereof.






